Depressive illness and the possibilities of somatic antidepressant treatment

International Journal of Technology Assessment in Health Care

Volumn 12, Issue 4, 1996, Pages 554-572

  Mårtensson, Björn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

DEPRESSION; ELECTROCONVULSIVE THERAPY; MOOD; MORTALITY; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS;

EID: 0030462780     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462300010886     Document Type: Review

References (139)

1. Abou-Saleh, M. T. Who responds to prophylactic lithium therapy? British Journal of Psychiatry, 1993, 163(suppl. 21), 20-26.
2. Abrams, R. Electroconvulsive therapy, 2nd ed. New York: Oxford University Press, 1992.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. Washington, DC: American Psychiatric Association, 1987.
4. American Psychiatric Association. Practice guideline for major depressive disorder in adults. American Journal of Psychiatry, 1993, 150(suppl.), 1-26.
5. American Psychiatric Association Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy. Washington DC: APA, 1990.
6. Anderson, I. M., & Tomenson, B. M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. British Medical Journal, 1995, 310, 1433-38.
7. Angst, J. The epidemiology of depressive disorders. European Neuropsychopharmacology, 1995, 5(suppl.), 95-98.
8. Åsberg, M., & Mårtensson, B. Serotonin selective antidepressant drugs: Past, present, future. Clinical Neuropharmacology. 1993, 16(suppl 3), S32-44.
9. Åsgård, U., Nordström, P., & Råbäck, G. Birth cohort analysis of changing suicide risk by sex and age in Sweden 1952 to 1981. Acta Psychiatrica Scandinavica, 1987, 76, 456-63.
10. Ayd, F. J. The early history of modern psychopharmacology. Neuropsychopharmacology, 1991, 5, 71-84.
11. Barden, N., Reul, J. M. H. M., & Holsboer, F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neurosciences, 1995, 18, 6-11.
12. Black, D. W., Winokur, G., Mohandoss, E., et al. Does treatment influence mortality in depressives? A follow-up of 1076 patients with major affective disorders. Annals of Clinical Psychiatry, 1989, 1, 165-73.
13. Blackwell, B. Hypertensive crisis due to monoamine oxidase inhibitors. Lancet, 1963, ii, 849-51.
14. Boissel, J.-P., Blanschard, J., Panak, E., et al. Considerations for the meta-analysis of randomized clinical trials. Controlled Clinical Trials, 1989, 10, 254-81.
15. Brown, G. W., Harris, T. O, & Hepworth, C. Life events and endogenous depression: A puzzle reexamined. Archives of General Psychiatry, 1994, 51, 525-34.
16. Brown, G. W., & Moran, P. Clinical and psychosocial origins of chronic depressive episodes, I: A community survey. British Journal of Psychiatry, 1994, 165, 447-56.
17. Coppen, A., Standish-Barry, H., Bailey, J., et al. Does lithium reduce the mortality of recurrent mood disorders? Journal of Affective Disorders, 1991, 23, 1-7.
18. Corruble, E., & Puech, A. J. How to improve the risk-benefit ratio of antidepressants. International Clinical Psychopharmacology, 1993, 8, 237-41.
19. IA receptor sensitivity in major depression: A neuroendocrine study with buspirone. British Journal of Psychiatry, 1994, 164, 372-79.
20. Cross-National Collaborative Group. The changing rates of depression: Cross-national comparisons. Journal of the American Medical Association, 1992, 268, 3099-105.
21. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology, 1986, 90, 131-38.
22. Danish University Antidepressant Group. Paroxetine: A selective reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 1990, 18, 289-99.
23. Davis, J. M. Antidepressant drugs. In M. I. Kaplan & B. J. Sadock (eds.) Comprehensive textbook of psychiatry. Baltimore: Williams & Wilkins, 1985, 1534-35.
24. Davis, M. Hepatotoxicity of antidepressants. International Clinical Psychopharmacology, 1991, 6, 97-103.
25. IA agonists in anxiety and depression. Journal of Psychopharmacology, 1993, 7, 283-89.
26. d'Elia, G. Comparison of electroconvulsive therapy with unilateral and bilateral stimulation, III: Anterograde amnesia. Acta Psychiatrica Scandinavica, 1970, 46(suppl. 215), 44-60.
27. Devanand, D. P., & Sackeim, H. A. Electroconvulsive therapy: Efficacy, side effects and mechanisms of action. In R. Pohl & S. Gershon (eds.), The biological basis of psychiatric treatment: Progress in basic and clinical pharmacology, vol. 3. Basel: Karger, 1990, 170-210.
28. IA receptor agonists: Recent developments and controversial issues. Psychopharmacology, 1995, 121, 1-26.
29. Dubovsky, S. L. Beyond the serotonin reuptake inhibitors: Rationales for the development of new serotonergic agents. Journal of Clinical Psychiatry, 1994, 55(suppl. 2), 34-44.
30. Edwards, J. G., Inman, W. H., Wilton, L., & Pearce, G. L. Prescription-event monitoring of 10401 patients treated with fluvoxamine. British Journal of Psychiatry, 1994, 164, 387-95.
31. Edwards, J. G. Suicide and antidepressants: Controversies on prevention, provocation, and self poisoning continue. British Medical Journal, 1995, 310, 205-06.
32. Ferrier, I. N. Comparisons of clinical efficay. British Journal of Psychiatry, 1993, 163(suppl. 20), 25-28.
33. Fink, M., & Ottosson, J.-O. A theory of convulsive therapy in endogenous depression: Significance of hypothalamic functions. Psychiatry Research, 1980, 2, 49-61.
34. Frank, E., Anderson, B., Reynolds , C. F., III, et al. Life events and the research diagnostic criteria endogenous subtype: A confirmation of the distinction using the Bedford College methods. Archives of General Psychiatry, 1994, 51, 519-24.
35. Freeman, H. Moclobemide. Lancet, 1993, 342, 1528-32.
36. Ghadirian, A. M., Engelsmann, F., Dhar, V., et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biological Psychiatry, 1995, 37, 369-75.
37. Gibbons, R. D., Clark, D. C., & Kupfer, D. J. Exactly what does the Hamilton depression rating scale measure? Journal of Psychiatric Research, 1993, 27, 259-73.
38. Gitlin, M. J. Lithium-induced renal insufficiency. Journal of Clinical Psychopharmacology, 1993, 13, 276-79.
39. Glue, P., Christensen, P., Lolk, A., et al. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders, 1993, 28, 105-16.
40. Goodwin, F. K., & Jamison, K. R. Manic-depressive illness. New York: Oxford University Press, 1990.
41. Gram, L. F. Inadequate dosing and pharmacokinetic variability as confounding factors in assessment of efficacy of antidepressants. Clinical Neuropharmacology, 1990, 13(suppl. 1), S35-44.
42. Greenberg, P. E., Stiglin, L. A., Finkelstein, S. N., & Berndt, E. R. The economic burden of depression in 1990. Journal of Clinical Psychiatry, 1993, 54, 405-18.
43. Guscott, R., & Grof, P. The clinical meaning of refractory depression: A view for the clinician. American Journal of Psychiatry, 1991, 148, 695-704.
44. Guscott, R., & Taylor, L. Lithium prophylaxis in recurrent affective illness: Efficacy, effectiveness and efficiency. British Journal of Psychiatry, 1994, 164, 741-46.
45. Hagnell, O., Lanke, J., Rorsman, B., & Öjesjö, L. Are we entering an age of melancholy? Depressive illness in a prospective epidemiological study over 25 years: The Lundby study, Sweden. Psychological Medicine, 1982, 12, 279-89.
46. Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 1960, 23, 56-62.
47. Hatziandreu, E. J., Brown, R. E., Revicki, D. A., et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. PharmacoEconomics, 1994, 5, 249-64.
48. Helgasson, T. The epidemiology of depressions. Nordic Journal of Psychiatry, 1990, 44, 3-12.
49. Heninger, G. R., Delgado, P. L., & Charney, D. S. The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry, 1996, 29, 2-11.
50. Henry, J. A. Debits and credits in the management of depression. British Journal of Psychiatry, 1993, 163(suppl. 20), 33-39.
51. Henry, J. A. The safety of antidepressants. British Journal of Psychiatry, 1992, 160, 439-41.
52. Hollon, S. D., DeRubeis, R. J., Evans, M. D., et al. Cognitive therapy and pharmacotherapy for depression: Singly and in combination. Archives of General Psychiatry, 1992, 49, 774-81.
53. Hyttel, J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology, 1994, 9(suppl. 1), 19-26.
54. Joffe, R. T., & Schuller, D. R. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depressions. Journal of Clinical Psychiatry, 1993, 54, 269-71.
55. Joffe, R. T., Singer, W., Levitt, A. J., & MacDonald, C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Archives of General Psychiatry, 1993, 50, 387-93.
56. Jönsson, B., & Bebbington, P. E. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. British Journal of Psychiatry, 1994, 164, 665-73.
57. Joyce, P. R., & Paykel, E. S. Predictors of drug response in depression. Archives of General Psychiatry, 1989, 46, 89-99.
58. Kallner, G., & Petterson, U. Renal, thyroid and parathyroid function during lithium treatment: Laboratory tests in 207 people treated for 1-30 years. Acta Psychiatrica Scandinavica, 1995, 91, 48-51.
59. Kasper, S. The rationale for long-term antidepressant therapy. International Clinical Psychopharmacology, 1993, 8, 225-35.
60. Katz, M. M., & Maas, J. W. Psycho pharmacology and the etiology of psychopathologic states: Are we looking in the right way? Neuropsychopharmacology, 1994, 10, 139-44.
61. Kessler, R. C., McGonagle, K. A., Zhao, S., et al. Life-time and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Archives of General Psychiatry, 1994, 51, 8-19.
62. Kind, P., & Sorensen, J. The costs of depression. International Clinical Psychopharmacology, 1993, 7, 191-95.
63. King, B. H., & Liston, E. H. Proposals for the mechanism of action of convulsive therapy: A synthesis. Biological Psychiatry, 1990, 27, 76-94.
64. Klerman, G. L. The age of melancholy? Psychology Today, 1979, April, 37-38.
65. Klerman, G. L., & Weissman, M. M. Increasing rates of depression. Journal of the American Medical Association, 1989, 261, 2229-35.
66. Kuhn, R. Über die Behandlung depressiver Zustände mit einem Iminodibenzyl Derivat (G 22355). Schweizerische Medizinische Wochenschrift, 1957, 87, 1135-40.
67. Kupfer, D. J., Frank, E., Perel, J. M., et al. Five-year outcome for maintenance therapies in recurrent depression. Archives of General Psychiatry, 1992, 49, 769-73.
68. Lam, R. W., Gorman, C. P., Michalon, M., et al. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. American Journal of Psychiatry, 1995, 152, 1765-70.
69. Lancet. Doubts about the value of maintenance lithium (editorial). Lancet, 1987, i, 424.
70. Lapierre, Y., Bentkover, J., Schainbaum, S., & Manners, S. Direct cost of depression: Analysis of treatment costs of paroxetine versus imipramine in Canada. Canadian Journal of Psychiatry, 1995, 40, 370-77.
71. Leibenluft, E., & Wehr, T. A. Is sleep deprivation useful in the treatment of depression? American Journal of Psychiatry, 1991, 149, 159-68.
72. Leonard, B. E. Serotonin receptors: Where are they going? International Clinical Psychopharmacology, 1994, 9(suppl. 1), 7-17.
73. Le Pen, C., Levy, V., Ravily, J. N., et al. The cost of treatment dropout in depression: A cost-benefit analysis of fluoxetine vs. tricyclics. Journal of Affective Disorders, 1994, 31, 1-18.
74. Lesch, K. P., Aulakh, C. S., Wolozin, B. L., et al. Regional brain expression of serotonin transporter messenger RNA and its regulation by reuptake inhibiting antidepressants. Molecular Brain Research, 1993, 17, 31-35.
75. Markowitz, J., Brown, R., Sweeney, J., & Mann, J. J. Reduced length and cost of hospital stay for major depression in patients treated with ECT. American Journal of Psychiatry, 1987, 144, 1025-29.
76. Mårtensson, B., & Åberg-Wistedt, A. Selektiva hämmare av serotoninupptag. Ny grupp antidepressiva ökar i anvandning. Läkartidningen, 1994, 91, 3371-79.
77. Mårtensson, B., Bartfai, A., Hallén, B., et al. A comparison of propofol and methohexithal as anesthetic agents for ECT: Effects on seizure duration, therapeutic outcome and memory. Biological Psychiatry, 1994, 35, 179-89.
78. McKenna, S. P., Hunt, S. M., & Tennant, A. Psychological well-being in depressed patients. International Journal of Methods in Psychiatric Research, 1993, 3, 245-51.
79. Medhus, A., Heskestad, S., & Tjemsland, L. Mianserin added to tricyclic antidepressants in depressed patients not responding to an antidepressant alone. Nordic Journal of Psychiatry, 1994, 48, 355-58.
80. Mellerup, E. T., & Plenge, P. The side effects of lithium (editorial). Biological Psychiatry, 1990, 28, 464-66.
81. Merikangas, K. R., Wicki, W., & Angst, J. Heterogeneity of depression: Classification of depressive subtypes by longitudinal course. British Journal of Psychiatry, 1994, 164, 342-48.
82. Meyer, U. A., Amrein, R., Balant, L. P., et al. Antidepressants and drug-metabolizing enzymes: Expert group report. Acta Psychiatrica Scandinavica, 1996, 93, 71-79.
83. Moncrieff, J. Lithium revisited: A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder (editorial). British Journal of Psychiatry, 1995, 167, 569-74.
84. Montgomery, S. A., & Åsberg, M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 1979, 134, 382-89.
85. Montgomery, S. A., & Dunbar, G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. International Clinical Psychopharmacology, 1993, 8, 189-95.
86. Montgomery, S. A., Henry, J., McDonald, G., et al. Selective serotonin reuptake inhibitors meta-analysis of discontinuation rates. International Clinical Psychopharmacology, 1994, 9, 47-53.
87. Mukherjee, S., Sackeim, H. A., & Schnur, D. B. Electroconvulsive therapy of acute manic episodes: A review of 50 years' experience. American Journal of Psychiatry, 1994, 151, 169-76.
88. Nierenberg, A. A. The treatment of severe depression: Is there an efficacy gap between SSRI and TCA antidepressant generations? Journal of Clinical Psychiatry, 1994, 55(suppl. A), 55-59.
89. NIH Consensus Development Panel on Depression in Late Life. Diagnosis and treatment of depression in late life. Journal of American Medical Association, 1992, 268, 1018-24.
90. Nilsson, B. S. Adverse reactions in connection with zimeldine treatment: A review. Acta Psychiatrica Scandinavica, 1983, 68(suppl. 308), 115-19.
91. Paykel, E. S. Life events, social support and depression. Acta Psychiatrica Scandinavica, 1994, suppl. 377, 50-58.
92. Paykel, E. S., Cooper, Z., Ramana, R., & Hayhurst, H. Life events, social support and marital relationships in the outcome of severe depression. Psychological Medicine, 1996, 26, 121-33.
93. Paykel, E. S., & Priest, R. G. Recognition and management of depression in general practice: Consensus statement. British Medical Journal, 1992, 305, 198-202.
94. Peet, M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry, 1994, 164, 549-50.
95. Phillips, K. A., & Nierenberg, A. A. The assessment and treatment of reactory depression. Journal of Clinical Psychiatry, 1994, 55(suppl. 2), 20-26.
96. Post, R. M., Ketter, T. A., Pazzaglia, P. J., et al. New developments in the use of anticonvulsants as mood stabilizers. Neuropsychobiology, 1993, 27, 132-37.
97. Priest, R. G. Improving the management and knowledge of depression: Marking 'Defeat of Depression Action Week' for the Defeat Depression Campaign (editorial). British Journal of Psychiatry, 1994, 164, 285-87.
98. Quitkin, F. M., Stewart, J. W., McGrath, P. J., et al. Columbia atypical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. British Journal of Psychiatry, 1993, 163(suppl. 21), 30-34.
99. Regier, D. A., Hirshfield, R. M. A., Goodwin, F. K., et al. The NIMH depression awareness, recognition, and treatment program: Structure, aims, and scientific basis. American Journal of Psychiatry, 1988, 145, 1351-57.
100. Revicki, D. A., & Luce, B. R. Methods of pharmacoeconomic evaluations of new medical treatments in psychiatry. Psychopharmacology Bulletin, 1995, 31, 57-65.
101. Revicki, D. A., Turner, R., Brown, R., & Martindale, J. J. Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment. Quality of Life Research, 1992, 1, 257-66.
102. Richelson, E. Treatment of acute depression. Psychiatric Clinics of North America, 1993, 16, 461-78.
103. Rifkin, A. ECT versus tricyclic antidepressants in depression: A review of the evidence. Journal of Clinical Psychiatry, 1988, 49, 3-7.
104. Rorsman, B., Gräsbeck, A., Hagnell, O., et al. A prospective study of first-incidence depression: The Lundby study, 1957-72. British Journal of Psychiatry, 1990, 156, 336-42.
105. Rouillon, F., Phillips, R., Serruier, D., et al. Rechutes de dépression unipolaire efficacité de la maprotiline. L'Encéphale, 1989, 15, 527-34.
106. Rutz, W., von Knorring, L., & Wålinder, J. Long-term effects of an educational program for general practitioners given by the Swedish Committe for the Prevention and Treatment of Depression. Acta Psychiatrica Scandinavica, 1992, 85, 457-67.
107. Sackeim, H. A., Devanand, D. P., & Prudic, J. Stimulus intensity, seizure threshold and seizure duration: Impact on the efficacy and safety of electroconvulsive therapy. Psychiatric Clinics of North America, 1991, 14, 803-42.
108. Sackeim, H. A., Prudic, J., & Devanand, D. P. Treatment of medication-resistant depression with electroconvulsive therapy. In A. Tasman, S. Goldfinger, & C. Kaufmann (eds.), Annual Review of Psychiatry, vol. 9. Washington, DC: American Psychiatric Press, 1990, 91-115.
109. Sackeim, H. A., Prudic, J., Devanand, D. P., et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. New England Journal of Medicine, 1993, 328, 839-46.
110. Salzman, C. Dealing with the sexual side effects of SSRI antidepressants. Journal of Practical Psychiatry and Behavioral Health, 1995, May, 37-39.
111. Scott, J., Eccleston, D., & Boys, R. Can we predict persistence of depression? British Journal of Psychiatry, 1992, 161, 633-37.
112. Simon, G., Ormel, J., VonKorff, M., & Barlow, W. Health care costs associated with depressive and anxiety disorders in primary care. American Journal of Psychiatry, 1995, 152, 352-57.
113. Simon, G. E., VonKorff, M., Üstün, T.B., et al. Is the lifetime risk of depression actually increasing? Journal of Clinical Epidemiology, 1995, 48, 1109-18.
114. Snaith, P. What do depression rating scales measure? British Journal of Psychiatry, 1993, 163, 293-98.
115. Song, F., Freemantle, N., Sheldon, T. A., et al. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. British Medical Journal, 1993, 306, 683-87.
116. Souza, F. G. M., & Goodwin, G. M. Lithium treatment and prophylaxis in unipolar depression: A meta-analysis. British Journal of Psychiatry, 1991, 158, 666-75.
117. Stein, G., & Bernadt, M. Lithium augmentation therapy in tricyclic-resistant depression: A controlled trial using lithium in low and normal doses. British Journal of Psychiatry, 1993, 162, 634-40.
118. Stephens, S. M., Pettinati, H. M., Greenberg, R. M., & Kelly, C. E. Continuation and maintenance therapy with outpatient ECT. In C. E. Coffey (ed.), The Clinical Science of Electroconvulsive Therapy: Progress in Psychiatry, vol. 38. Washington, DC: American Psychiatric Press, 1993, 143-64.
119. Sternbach, H. The serotonin syndrome. American Journal of Psychiatry, 1991, 148, 705-13.
120. Stoker, M. J., Dunbar, G. C., & Beaumont, G. The SmithKline Beecham 'quality of life' scale: A validation and reliability study in patients with affective disorder. Quality of Life Research, 1992, 1, 385-95.
121. Stokes, P. E. Current issues in the treatment of major depression. Journal of Clinical Psychopharmacology, 1993, 13(suppl. 2), S2-9.
122. Stuppaeck, C., Barnas, C., Schwitzer, J., & Fleischhacker, W. W. The role of carbamazepinein the prophylaxis of unipolar depression. Neuropsychobiology, 1993, 27, 154-57.
123. Surtees, P. G., & Barkley, C. Future imperfect: The long-term outcome of depression. British Journal of Psychiatry, 1994, 164, 327-41.
124. Swartz, C. M. Beyond seizure duration as a measure of treatment quality (editorial). Convulsive Therapy, 1993, 9, 1-7.
125. Thase, M. E., Frank, E., Mallinger, A. G., et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. Journal of Clinical Psychiatry, 1992, 53, 5-11.
126. Thies-Flechtner, K., Müller-Oerlinghausen, B., Seibert, W., et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: Data from a randomized prospective trial. Pharmacopsychiatry, 1996, 29, 103-07.
127. Üstün, T. B., & Sartorius, N. Public health aspects of anxiety and depressive disorders. International Clinical Psychopharmacology, 1993, 8(suppl. 1), 15-20.
128. Vanselow, W., Dennerstein, L., Armstrong, S., & Lockie, P. Retinopathy and bright light (letter). American Journal of Psychiatry, 1991, 148, 1266-67.
129. Verhoeven, V. M. A., & Tuinier, S. Affective and aggressive behavioral disorders: Thoughts about diagnosis and etiology. New Trends in Experimental and Clinical Psychiatry, 1993, 9, 123-36.
130. Vestergaard, P. Treatment and prevention of mania: A Scandinavian perspective. Neuropsychopharmacology, 1992, 7, 249-59.
131. Wehr, T. A., & Goodwin, F. K. Can antidepressants cause mania and worsen the course of affective illness? American Journal of Psychiatry, 1987, 144, 1403-11.
132. Weissman, M. M., & Markowitz, J. C. Interpersonal psychotherapy. Current status. Archives of General Psychiatry, 1994, 51, 599-606.
133. Wells, K. B., Rogers, W., Burnam, M. A., & Camp, P. Course of depression in patients with hypertension, myocardial infarction, or insulin-dependent diabetes. American Journal of Psychiatry, 1993, 150, 632-38.
134. Wetterberg, L. Light and biological rhythms. Journal of Internal Medicine, 1994, 235, 5-19.
135. WHO Mental Health Collaborating Centres. Pharmacotherapy of depressive disorders: A consensus statement. Journal of Affective Disorders, 1989, 17, 197-98.
136. Williams, R., Edwards, R. A., Newburn, G. M., et al. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. International Clinical Psychopharmacology, 1993, 7, 155-58.
137. Zachrisson, O., Mathé, A. A., Stenfors, C., & Lindefors, N. Limbic effects of repeated electroconvulsive stimulation on neuropeptide Y and somatostatin mRNA in the rat brain. Molecular Brain Research, 1995, 31, 71-85.
138. Zajecka, J. M., & Fawcett, J. Antidepressant combination and potentiation. Psychiatric Medicine, 1991, 9, 55-75.
139. Zajecka, J. M., & Fawcett, J. Innovative somatic treatments for depression. Psychiatric Medicine, 1991, 9, 77-103.